JP Morgan Initiates Coverage On Kestra Medical Techs with Overweight Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Positive 49.8%

Neg 0% Neu 0% Pos 49.8%

JP Morgan analyst Robbie Marcus initiates coverage on Kestra Medical Techs (NASDAQ:KMTS) with a Overweight rating and announces Price Target of $30.